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Therefore, in pituitary tumorigenesis EMT likely occurs within a specific genetic context and may be related to their increased local invasion and aggressive phenotype which may contribute to treatment resistance.
We have also demonstrated that lack of AIP plays a critical role in cellular invasion; these changes may recapitulate the in vivo situation.
This study has important implications for our understanding of the molecular basis of AIPpos pituitary tumourigenesis. Identified genes may predict the invasive potential of these tumours and provide new opportunity to develop therapies. 
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Validation by RT-qPCR (cont.)
Familial isolated pituitary adenoma (FIPA) is an autosomal dominant condition with incomplete penetrance. Heterozygote mutations have been identified in the arylhydrocarbon receptor interacting protein (AIP) gene in 20% of FIPA families. In AIP positive patients, the disease is occurring at a younger age and have larger, more aggressive tumours than AIP negative patients and often show invasion at the time of diagnosis as well as poor response to somatostatin analogues than sporadic tumours 1,2 .
Aims
The aim of this study was to perform comparative gene expression microarray analysis of familial AIP positive and AIP negative adenomas and compare them to sporadic tumours and normal pituitary to discover novel genes and pathways responsible for familial pituitary tumorigenesis.
Methods
We have performed gene expression analysis on normal pituitary, sporadic GH-secreting adenomas, AIP positive and AIP negative familial somatotroph adenomas (five samples of each category) using the Affymetrix human Gene Chip HG-U133 Plus 2.0 array. Data analysis was carried out in the statistical 'R' environment. Ingenuity Pathway Analysis (IPA) tool was used for pathway analysis. Expression of the ten selected genes from microarray analysis was validated by quantitative reverse transcriptase PCR. Functional assays were performed using BioCoat-Matrigel invasion chambers. 
